Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-41-729-7194
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
When did Auris Medical's stock split? How did Auris Medical's stock split work?
Auris Medical shares reverse split before market open on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.
How were Auris Medical's earnings last quarter?
Auris Medical Holding Ltd (NASDAQ:EARS) announced its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
1 brokerages have issued 1-year price objectives for Auris Medical's shares. Their forecasts range from $100.00 to $100.00. On average, they expect Auris Medical's share price to reach $100.00 in the next twelve months. This suggests a possible upside of 6,992.2% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
Headlines about EARS stock have been trending very positive on Wednesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Auris Medical earned a news impact score of 3.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Auris Medical.
Are investors shorting Auris Medical?
Auris Medical saw a drop in short interest in October. As of October 31st, there was short interest totalling 39,800 shares, a drop of 38.0% from the September 30th total of 64,200 shares. Based on an average daily volume of 133,500 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.5% of the company's shares are sold short. View Auris Medical's Current Options Chain.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Lipocine (LPCN), GT Biopharma (GTBP), Acura Pharmaceuticals (ACUR), Earth Science Tech (ETST), Kaya (KAYS), Neurotrope (NTRP), iCo Therapeutics (ICOTF), Novus Therapeutics (NVUS), NeuroVive Pharmaceutical (NEVPF), BENITEC BIOPHAR/S (BNTC), Sonoma Pharmaceuticals (SNOA), Trillium Therapeutics (TRIL), Capricor Therapeutics (CAPR), Integrated BioPharma (INBP) and Tetraphase Pharmaceuticals (TTPH).
What other stocks do shareholders of Auris Medical own?
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
- Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
- Colleen A. DeVries, SVP of Cogency Global Inc.
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $1.41.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $2.64 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
